Joseph Zenga

Joseph Zenga

Auto-generated profile, based on publicly available information

Joseph Zenga

Department of Otolaryngology and Communication Sciences Medical College of Wisconsin Milwaukee Wisconsin USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Oral Oncology
Verified
Journal Article
Closed access
JZJoseph Zenga
Joseph Zenga
TGTessa Goldsmith
Tessa Goldsmith
GBGlenn Bunting
Glenn Bunting
DDDaniel G. Deschler
Daniel G. Deschler

11 July 2017 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PVPeter M Vila
Peter M Vila
JZJoseph Zenga
Joseph Zenga
RJRyan S Jackson
Ryan S Jackson

1 September 2015 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
JZJoseph Zenga
Joseph Zenga
DKDaniel Kreisel
Daniel Kreisel
VKVladimir M. Kushnir
Vladimir M. Kushnir
JRJason T. Rich
Jason T. Rich

20 April 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
JZJoseph Zenga
Joseph Zenga
JSJasmina Suko
Jasmina Suko
DKDorina Kallogjeri
Dorina Kallogjeri
PPPatrik Pipkorn
Patrik Pipkorn
BNBrian Nussenbaum
Brian Nussenbaum
RJRyan S. Jackson
Ryan S. Jackson

22 August 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MBMustafa G. Bulbul
Mustafa G. Bulbul
JZJoseph Zenga
Joseph Zenga
OTOsama Tarabichi
Osama Tarabichi
APAnuraag S. Parikh
Anuraag S. Parikh
RSRosh K. Sethi
Rosh K. Sethi
MVMark A. Varvares
Mark A. Varvares

1 November 2018 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
JZJoseph Zenga
Joseph Zenga
APAnuurag S. Parikh
Anuurag S. Parikh
KEKevin S. Emerick
Kevin S. Emerick
DLDerrick T. Lin
Derrick T. Lin
WFWilliam C. Faquin
William C. Faquin
DDDaniel G. Deschler
Daniel G. Deschler
Importance The precise indications and oncologic effects of adjuvant radiotherapy in acinic cell carcinoma of the parotid gland are not well known, particularly in patients with negative, but close (≤1 mm), margins without other high-risk histopathologic factors. Objective To evaluate the oncologic outcomes of patients with acinic cell carcinoma of the parotid gland and the results of adjuvant therapy for those with close (≤1-mm) margins. Design, Setting, and Participants In a retrospective case series with medical record review at a single academic tertiary referral center, patients treated surgically from January 2000 to December 2014 for acinic cell carcinoma of the parotid gland were identified from an institutional database. All data analysis was performed in September 2017. Exposures All patients underwent parotidectomy with or without adjuvant radiotherapy or chemoradiotherapy. Main Outcomes and Measures The primary end point was locoregional control. Secondary end points included recurrence patterns and survival. Results Forty-five patients were identified in this case series (23 [51%] female), with a mean (SD) age of 47.1 (19.5) years. The median follow-up in surviving patients was 56.7 months (range, 18.5-204 months). Four patients (9%) experienced recurrence (1 local and 3 distant) at a median of 67.3 months (range, 12.7-136 months) after surgery. Thirteen patients (29%) had at least one high-risk histopathologic factor (advanced T category, nodal disease, lymphovascular or perineural invasion, high-grade, or positive margins). The remaining 32 patients (71%) without these high-risk factors had significantly improved disease-free survival (hazard ratio, 0.08; 95% CI, 0.01-0.71). Of patients without high-risk factors, those with close (≤1-mm) margins were significantly more likely to receive adjuvant radiotherapy (10 [56%] vs 1 [7%]; difference, 49%; 95% CI, 16%-82%), although this was not associated with disease control. At a median follow-up of 64.3 months (range, 33-204 months) in the 18 patients with close (≤1-mm) margins without other high-risk factors (10 with adjuvant radiotherapy and 8 without adjuvant therapy), only 1 patient (who had received adjuvant radiotherapy) experienced a recurrence, at 136 months after surgery. Conclusions and Relevance Patients with acinic cell carcinoma of the parotid gland whose only histopathologic risk factor is a close (≤1 mm) but negative margin do not appear to benefit from adjuvant radiotherapy. Recurrent disease is rare but may occur many years after initial treatment, and patients with acinic cell carcinoma could benefit from lifelong clinical surveillance.